Empagliflozin Attenuates Non-Alcoholic Fatty Liver Disease (NAFLD) in High Fat Diet Fed ApoE<sup>(-/-)</sup> Mice by Activating Autophagy and Reducing ER Stress and Apoptosis
Aims/hypothesis: SGLT-2 inhibitors (SGLT-2i) have been studied as potential treatments against NAFLD, showing varying beneficial effects. The molecular mechanisms mediating these effects have not been fully clarified. Herein, we investigated the impact of empagliflozin on NAFLD, focusing particularl...
Main Authors: | Narjes Nasiri-Ansari, Chrysa Nikolopoulou, Katerina Papoutsi, Ioannis Kyrou, Christos S. Mantzoros, Georgios Kyriakopoulos, Antonios Chatzigeorgiou, Vassiliki Kalotychou, Manpal S. Randeva, Kamaljit Chatha, Konstantinos Kontzoglou, Gregory Kaltsas, Athanasios G. Papavassiliou, Harpal S. Randeva, Eva Kassi |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-01-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/22/2/818 |
Similar Items
-
Anti-osteoporotic treatments in the era of non-alcoholic fatty liver disease: friend or foe
by: Maria Eleni Chondrogianni, et al.
Published: (2024-03-01) -
Genetic and Diet-Induced Animal Models for Non-Alcoholic Fatty Liver Disease (NAFLD) Research
by: Christina-Maria Flessa, et al.
Published: (2022-12-01) -
Endothelial Cell Dysfunction and Nonalcoholic Fatty Liver Disease (NAFLD): A Concise Review
by: Narjes Nasiri-Ansari, et al.
Published: (2022-08-01) -
Estrogen Receptor Subtypes Elicit a Distinct Gene Expression Profile of Endothelial-Derived Factors Implicated in Atherosclerotic Plaque Vulnerability
by: Narjes Nasiri-Ansari, et al.
Published: (2022-09-01) -
SGLT-2 Inhibitors in NAFLD: Expanding Their Role beyond Diabetes and Cardioprotection
by: Theodoros Androutsakos, et al.
Published: (2022-03-01)